Type II Collagen: Evidence, Dosage, UC-II, and Label Guide

Type II collagen may appear on supplement labels as native type II collagen, undenatured type II collagen, non-hydrolyzed type II collagen, UC-II®, or a named chicken-cartilage ingredient. These descriptions are not automatically equivalent, and low-dose native type II collagen should not be evaluated as if it were hydrolyzed collagen peptides.

Type II collagen is a major structural protein in cartilage. In supplements, the most studied low-dose form is native or undenatured type II collagen, usually derived from chicken sternum cartilage. Randomized trials of specific proprietary preparations have reported improvements in selected knee-pain, stiffness, function, or range-of-motion outcomes. The evidence is not uniform, however, and much of it is manufacturer-funded or written by authors with commercial ties. Type II collagen may support symptoms in some users, but human trials have not shown that it regrows lost cartilage or reverses osteoarthritis.

What is type II collagen?

Collagen is a family of structural proteins rather than a single ingredient. Type II collagen is strongly associated with hyaline cartilage, including the articular cartilage that covers the ends of bones inside joints.

Most low-dose type II collagen supplements use chicken sternum cartilage. Manufacturing can preserve the protein’s native three-dimensional structure, denature that structure, hydrolyze the protein into smaller peptides, or combine denaturation and hydrolysis. Those differences affect the proposed mechanism, the dose used in research, and which clinical trials are relevant.

A label that says only collagen type II has not provided enough information to determine whether the ingredient belongs to the low-dose native category or to a hydrolyzed collagen category.

Native and undenatured are not the same claim as non-hydrolyzed

In this supplement category, native and undenatured are commonly used to describe material intended to retain relevant parts of the original collagen structure and antigenic sites. These terms still do not prove that two products have the same composition, stability, or biological activity.

Non-hydrolyzed is a weaker description. It says the collagen has not been deliberately broken into small peptides, but it does not by itself prove that the native triple-helical structure or antigenic regions survived processing. A protein can be denatured without being hydrolyzed.

One laboratory comparison reported substantial differences between commercial products labeled as undenatured type II collagen, including differences in physical properties and measured antigenic potential. The paper was later followed by a correction disclosing prior commercial relationships and by a methodological rejoinder from the manufacturer of one product tested. The study therefore supports caution about assuming interchangeability, but it should not be treated as a definitive ranking of commercial ingredients. ^[9]

Undenatured type II collagen versus collagen peptides

Hydrolyzed collagen peptides have been broken into shorter protein fragments and are usually studied in gram-level servings. Native or undenatured type II collagen is generally taken in much smaller milligram amounts.

The low-dose category is not intended to supply a large amount of amino acids as cartilage building material. Its proposed mechanism involves interaction between preserved collagen structures and immune tissue in the gut, potentially promoting oral tolerance. Detailed support for that mechanism comes mainly from laboratory and animal research. Human trials have measured symptoms, function, flexibility, and selected biomarkers rather than directly proving the full immune pathway.

What do human trials show for knee osteoarthritis?

The more informative positive evidence comes from randomized trials of specific native or undenatured preparations. The findings are relevant, but the evidence base is commercially concentrated and should not be generalized to every product carrying the words type II collagen.

Six-month UC-II trial

A 2016 multicenter trial randomized 191 adults with knee osteoarthritis to 40 mg per day of UC-II, glucosamine hydrochloride plus chondroitin sulfate, or placebo for 180 days. The UC-II group had a greater reduction in total WOMAC score than both comparison groups at day 180, with reported benefits in pain, stiffness, and physical-function subscales.^[1]

This is one of the more informative studies because it included a placebo, an active comparator, and six months of follow-up. It was also sponsored by the ingredient company: two authors were company employees and the third had provided consulting services. The result supports the tested UC-II preparation, not automatic equivalence across all chicken-cartilage products.

Twelve-week Native CT-II trial

A 2022 trial randomized 101 adults with knee osteoarthritis to 40 mg of Native CT-II, glucosamine hydrochloride plus chondroitin sulfate, or placebo for twelve weeks. The final analysis included 29 participants in each active group and 27 in the placebo group. Both active groups improved more than placebo on total WOMAC and knee-pain measures.^[2]

The study was funded by the manufacturer of the tested ingredient, one author was employed by that company, and the clinical work involved a contract research organization. It adds preparation-specific evidence, but it is not independent replication of the entire category.

Smaller and mixed studies

A 39-person trial tested 10 mg of native type II collagen as an addition to 1,500 mg per day of acetaminophen. Walking pain improved more in the combination group, while most other between-group comparisons and urinary cartilage-degradation biomarkers were less decisive. Because the study tested an add-on intervention rather than type II collagen alone against placebo, its conclusion should remain tied to that design.^[3]

A non-industry-funded 2025 trial provides useful counterweight. Sixty-eight adults with knee osteoarthritis received a daily combination of 40 mg undenatured type II collagen and 960 mg hydrolyzed collagen, or placebo, for twelve weeks. Pain and function improved in both groups, but the collagen combination did not significantly outperform placebo for pain, KOOS function, rescue medication use, or satisfaction. Because two collagen forms were combined, the study cannot isolate the effect of either one.^[4]

What do studies in otherwise healthy adults show?

Several proprietary ingredients have also been tested in adults without diagnosed arthritis who developed knee discomfort during standardized exercise. These trials are relevant to activity-related discomfort and flexibility, but they should not be reframed as evidence that the supplement prevents injury or future osteoarthritis.

In a 2013 trial, 55 adults received 40 mg of UC-II or placebo for 120 days. The UC-II group improved knee extension compared with placebo. Time to initial discomfort improved from baseline, although some pain-onset and recovery analyses involved smaller subsets of participants.^[5]

A 2022 trial randomized 96 active adults with exercise-related joint discomfort to 40 mg of UC-II or placebo for 24 weeks. Mean knee-flexion range of motion increased by 3.23 degrees with UC-II and by 0.21 degrees with placebo. Three authors were employees of the ingredient company, and the absolute difference was modest.^[6]

A 2026 trial enrolled 74 adults with exercise-related knee discomfort and tested 40 mg per day of a native type II collagen preparation for 180 days. The prespecified primary outcome, time until discomfort began during exercise, did not differ between groups. A between-group difference appeared in recovery time after one of three exercise tests, but not the other two, and the six-minute walk test was neutral. Selected KOOS and biomarker differences appeared mainly in prespecified subgroups or secondary analyses. The study had no multiplicity correction, a strong placebo response in part of the sample, manufacturer funding, and extensive author ties to the manufacturer.^[7]

Taken together, these studies suggest a possible preparation-specific effect on selected flexibility or activity-discomfort outcomes. They do not establish broad athletic-performance enhancement, injury prevention, or structural joint protection.

Does type II collagen rebuild cartilage?

Human trials have not established that oral native type II collagen regrows lost cartilage, reverses structural osteoarthritis, or repairs a bone-on-bone joint. Most studies measured pain questionnaires, WOMAC or KOOS scores, range of motion, exercise tolerance, or functional tests.

Biomarkers such as urinary CTX-II are not direct images of cartilage. In the 2026 trial, the overall CTX-II comparison was not significant; a difference appeared only in a subgroup with greater baseline discomfort. A subgroup biomarker result is hypothesis-generating, not proof of cartilage preservation.

Claims such as rebuilds cartilage, regenerates joints, or reverses osteoarthritis go beyond the outcomes demonstrated in the human trials.

What does the 40 mg dose actually mean?

Forty milligrams is the best-known daily amount in this category, but it is not a universal dose of purified type II collagen. In the 2013 UC-II trial, 40 mg of the proprietary material supplied approximately 10.4 ± 1.3 mg of native type II collagen.^[5] The remaining material was part of the characterized cartilage ingredient, not another 30 mg of purified native collagen.

Other preparations use different specifications. A randomized trial of NEXT-II supplied 3.2 mg per day of undenatured type II collagen, while the acetaminophen add-on trial used 10 mg per day of native type II collagen.^[8][3]

Therefore, the following declarations are not automatically equivalent: 40 mg UC-II, 40 mg of generic chicken sternum cartilage, 40 mg of undenatured type II collagen, or 10 mg of measured native type II collagen. A study match requires more than an identical headline number.

Is more type II collagen better?

Current human evidence does not establish a clear dose-response relationship in which a larger amount produces a better outcome. This is not a protein-powder model where more grams necessarily provide more amino acids. For native preparations, retained structure, analytical characterization, stability, and preparation-specific clinical evidence may matter more than maximizing the total amount of cartilage powder.

A 500 mg generic cartilage ingredient is not automatically stronger than a 40 mg clinically studied native preparation. The opposite shortcut is also unsafe: a tiny dose should not receive efficacy credit merely because the front label uses the word undenatured.

UC-II is a branded ingredient, not a generic synonym

UC-II® is a proprietary undenatured type II collagen preparation. It should not be used as the generic name for every native type II collagen supplement. Other preparations can differ in processing, measured native collagen content, analytical methods, excipients, stability, and clinical evidence.

An unnamed chicken-cartilage powder cannot reasonably inherit UC-II trial results unless the manufacturer provides evidence that the marketed ingredient matches the studied preparation in identity, specification, dose, and relevant manufacturing characteristics.

How to read a type II collagen label

Start with identity, not the front-label claim. A useful label or technical specification should let you determine the following:

• whether the ingredient is native/undenatured, hydrolyzed, or simply generic cartilage;
• the animal and tissue source, commonly chicken sternum cartilage;
• the total ingredient amount per daily serving;
• the amount of measured native or undenatured type II collagen, if separately specified;
• the named proprietary preparation used in any cited human study.

Red flags include missing form information, borrowing evidence from a different branded preparation, presenting 40 mg as 40 mg of pure native collagen without a specification, hiding the ingredient inside a proprietary blend, or converting symptom improvements into cartilage-regeneration claims.

How long was type II collagen studied?

Better-known randomized trials lasted about twelve weeks to six months. That does not establish one universal onset time, because the studies used different preparations, populations, and outcomes. A claim such as works in seven days needs direct evidence for the exact marketed product; it cannot be inferred from a trial whose main assessment occurred months later.

Study instructions also varied. Some products were taken before bedtime, while others were taken with or around meals. There is no strong comparative human evidence showing that one fasting schedule or time of day is necessary for every native type II collagen product.

Side effects and safety limitations

Native or undenatured type II collagen was generally well tolerated in the randomized trials discussed here, with no consistent excess of adverse events versus placebo. The studies were still too small and too short to exclude rare reactions or establish long-term safety across all commercial preparations.

Most studied ingredients were derived from chicken cartilage. Source disclosure matters for people with a known allergy to chicken-derived ingredients and for vegetarian, vegan, religious, or ethical requirements. At least some trials excluded participants with known egg or chicken hypersensitivity, so trial tolerability should not be interpreted as proof of safety in allergic individuals.

Evidence is insufficient for confident routine-use recommendations during pregnancy, breastfeeding, childhood, or in people with complex medical conditions. Persistent swelling, locking, instability, fever, a recent injury, severe unexplained pain, or rapidly worsening mobility warrants medical assessment rather than being treated as a generic collagen problem.

How NutriDetector evaluates type II collagen supplements

NutriDetector first identifies whether the label describes native or undenatured type II collagen, hydrolyzed collagen, generic cartilage, a named proprietary ingredient, or an incompletely disclosed blend. Native and hydrolyzed forms are evaluated separately; a gram-level collagen-peptide threshold is not applied to a low-dose native preparation.

The analysis preserves both the total material amount and any separately declared native type II collagen amount. A 40 mg proprietary preparation may match a trial even when it supplies substantially less than 40 mg of measured native collagen. Conversely, 40 mg of an unnamed cartilage powder does not receive study-match credit merely because the number is familiar.

Evidence confidence is reduced when a claim relies on a different preparation, a combination product, only within-group improvement, exploratory subgroups, uncorrected multiple comparisons, or a biomarker that is being used as a substitute for direct structural evidence. Manufacturer funding does not invalidate a result, but it remains visible because independent replication is limited in this category.

Evidence-based bottom line

Native or undenatured type II collagen is a legitimate supplement category with several randomized human trials. Specific proprietary preparations have produced improvements in selected knee-pain, stiffness, function, flexibility, and exercise-discomfort outcomes.

The evidence is preparation-specific and not uniformly positive. Several effects are modest, some depend on secondary outcomes or subgroups, placebo response is important, and commercial involvement is extensive. A recent non-industry-funded trial of a native-plus-hydrolyzed collagen combination did not outperform placebo over twelve weeks.

The most defensible interpretation is that a well-characterized native type II collagen preparation may support selected joint symptoms in some users. It has not been shown to regrow lost cartilage or reverse osteoarthritis. A trustworthy label identifies exactly what the small milligram number represents; otherwise the number is doing more marketing work than scientific work.

FAQ: Type II collagen supplements